Skip to content

Cyclic boronates as versatile scaffolds for KPC-2 β-lactamase inhibition

Research output: Contribution to journalArticle

Original languageEnglish
Number of pages6
JournalMedicinal Chemistry
Early online date10 Jan 2020
DateAccepted/In press - 8 Jan 2020
DateE-pub ahead of print (current) - 10 Jan 2020


Klebsiella pneumoniae carbapenemase-2 (KPC-2) is a serine-β-lactamase (SBL) capable of hydrolysing almost all β-lactam antibiotics. We compare KPC-2 inhibition by vaborbactam, a clinically-approved monocyclic boronate, and VNRX-5133 (taniborbactam), a bicyclic boronate in late-stage clinical development. Vaborbactam inhibition is slowly reversible, whereas taniborbactam has an off-rate indicating essentially irreversible complex formation and a 15-fold higher on-rate, although both potentiate β-lactam activity against KPC-2-expressing K. pneumoniae. High resolution X-ray crystal structures reveal closely related binding modes for both inhibitors to KPC-2, with differences apparent only in positioning of the endocyclic boronate ester oxygen. The results indicate the bicyclic boronate scaffold as both an efficient, long-lasting, KPC-2 inhibitor and capable of supporting further iterations that may improve potency against specific enzyme targets and pre empt the emergence of inhibitor resistant KPC-2 variants.

Download statistics

No data available



  • Full-text PDF (accepted author manuscript)

    Rights statement: This is the author accepted manuscript (AAM). The final published version (version of record) is available online via Rpyal Society of Chemistry at!divAbstract. Please refer to any applicable terms of use of the publisher.

    Accepted author manuscript, 520 KB, PDF document


View research connections

Related faculties, schools or groups